Contact
News

Tetra Discovery Partners Featured in Life Science Leader as a Company to Watch

Tetra Discovery Partners

A determined young company revisits a discarded mechanism and finds a new path to broad-based therapeutics for cognition-related diseases such as Alzheimer’s.

SNAPSHOT

Tetra is developing a new class of phosphodiesterase 4 (PDE4)-inhibitor drugs to treat patients with a wide variety of “cognition-impairing” conditions. Its lead product, a PDE4D inhibitor (BPN14770), will enter Phase 1 human trials in Alzheimer’s disease this year, and two other pipeline candidates are PDE4B inhibitors in preclinical development for treating neuroinflammation and traumatic brain injury.

Read the rest of the article.

0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Time limit is exhausted. Please reload the CAPTCHA.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>